Previous news
InnoBio invests €750,000 in the Sensorion company
Financing companies - 18 April 2012
Within the framework of the FSI France Investissement Programme, the InnoBio Fund, managed by CDC Entreprises and specialized in the biotechnology, invests €750,000 in the Sensorion company, so realizing its ninth investment.
Sensorion is a young pharmaceutical company which is a pioneer in the field of pathology relating to the inner ear. The prevention and the treatment of this kind of pathology is a new market estimated to be worth several billion Dollars.
Sensorion has established an integrated platform of tests in vivo and in vitro which have allowed it to make rapid progress in the understanding of this kind of pathology and to identify new active compounds. Created in 2009, the company has been supported since its creation by Inserm Transfert Initiative.
The investment of InnoBio in Sensorion also shows the complementariness of the direct and indirect investment activity conducted by CDC Entreprises, a partner of Inserm Transfert Initiative since 2006. Sensorion thus joins more than 1,100 companies already with the label FSI France Investissement.
InnoBio is a Fonds commun de placement à risque (FCPR - joint venture capital fund) of €139mn, managed by CDC Entreprises and subscribed by the Fonds stratégique d’investissement (Strategic Investment Fund) (37 %) and the main global pharmaceutical laboratories (Sanofi Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer-Ingelheim) operating on French territory. Launched in 2010, its principal objective is to invest directly with equity and quasi-equity in the share capital of companies supplying technological and innovative products and services in the health field.
